Abstract 109P
Background
With 18F-FDG PET/CT, tumor uptake intensity and textural features have been associated with outcome in several types of cancer. This study was to evaluate the prognostic value of pretreatment 18F-FDG PET/CT textural parameters in patients with primary metastatic colorectal cancer (CRC).
Methods
All patients (n = 104) who had had a pretreatment image of 18F-FDG PET/CT at our Hospital from January 2009 to December 2015 were included. Volumes of interest (VOIs) were drawn freehand around the tumor, and texture analysis was conducted on both CT and PET images within the same VOIs. A total of 35 features were extracted and analyzed. Univariate and multivariate analyses (logistic regression) were conducted to assess the prognostic value of textural parameters. Moreover, radiomics score (rad-score) was constructed using logistic regression. A multivariate logistic regression model was then used to establish a nomogram including the rad-score and other clinicopathological features.
Results
The results of univariate analysis showed that 18 textural parameters such as skewness and kurtosis were significantly associated with survival. In multivariate model, 17 textural parameters were shown to be able to predict PFS, including skewness (HR 2.777, p < 0.001), kurtosis (HR 0.441, p < 0.001), entropy (HR 1.704, p = 0.014), homogeneity (HR 0.548, p = 0.006), SRE (HR 1.853, p = 0.005), LRE (HR, p = 0.005), HGRE (HR 1.616, p = 0.036), LZE (HR 0.597, p = 0.018), LGZE (HR 0.439, p < 0.001) and HGZE (HR 2.085, p = 0.001). In addition, 8 textural parameters such as skewness (HR 4.475, p < 0.001), kurtosis (HR 0.377, p < 0.001), SRHGE (HR 2.062, p = 0.005) and LRLGE (HR 0.475, p = 0.003), were revealed to be independent predictors of OS among our population.
Conclusions
The texture analysis of the baseline 18F-FDG PET/CT appears to be a potential tool to predict outcomes of patients with primary metastatic CRC. However, prospective studies with a large population are needed to confirm the present findings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
465P - A phase IIIb open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: Exploratory biomarker analysis
Presenter: Jie Wang
Session: Poster display session
Resources:
Abstract
470P - Prognostic significance of serum biomarkers in small cell lung cancer: A meta-analysis and systematic review
Presenter: Rogelio Velasco
Session: Poster display session
Resources:
Abstract
471P - Chemotherapy in advanced thymic malignancies
Presenter: Ankur Varshney
Session: Poster display session
Resources:
Abstract
466P - Cancer immunotherapy efficacy and patients’ age: A systematic review and meta-analysis
Presenter: Yu Jiang
Session: Poster display session
Resources:
Abstract
506P - Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC)
Presenter: Jeffrey Ward
Session: Poster display session
Resources:
Abstract
480P - Safety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050
Presenter: Tony S.K. Mok
Session: Poster display session
Resources:
Abstract
503P - Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials
Presenter: Antonio Passaro
Session: Poster display session
Resources:
Abstract
488P - Randomized trial of prophylactic minocycline for erlotinib-associated skin rash in non-small cell lung cancer (PEARL trial)
Presenter: Kei Kusaka
Session: Poster display session
Resources:
Abstract
495P - Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
Presenter: Anna Buder
Session: Poster display session
Resources:
Abstract
520P - A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)
Presenter: Akito Hata
Session: Poster display session
Resources:
Abstract